Session 1

Welcome and Program Overview
Jean de la Rosette (The Netherlands)

(2,55MB)

What constitutes clinical significant lesions
Mark Emberton (United Kingdom)

(8MB)

Anterior-predominant prostate cancer: diagnostic and therapeutic implications
Ferran Algaba (Spain)

(1,47MB)

Saturation biopsy vs 3D spatial biopsy vs hand guided ultrasound biopsy
John Ward (USA)

(5,45MB)

Session 2

MRI to detect prostate cancer
Jelle Barentsz (The Netherlands)

(21,5MB)

MRI in detecting local recurrences after treatment
Olivier Rouviere (France)

(3,76MB)

MRI directed focal therapy
Scott Eggener (USA)

(49MB)

Session 3

MRI guided prostate biopsy technique (video)
John Ward (USA)

N/A

MRI focal therapy of low-risk prostate cancer (video)
Jurgen Futterer (The Netherlands)

N/A

CEUS in Prostate Cancer
Hessel Wijkstra (The Netherlands)

(105MB)

Session 4

Contrast Enhanced ultrasound imaging
Maria Luigia Storto (USA)

N/A

Elastography
Ferdinand Frauscher (Austria)

(40,1MB)

Image fusion
Peter Pinto (USA)

(44,9MB)

Biomakers in addition to Imaging
Ralf Hoffman (The Netherlands)

N/A

Session 5

Focus on patient selection
Andrea Losa (Italy)

(1,57MB)

Hemi-Ablation with Cryo
Thomas Polascik (USA)

(3,62MB)

Hemi-ablation with HIFU
Sebastian Crouzet (France)

(2,16MB)

How interpret PSA changes after Focal Therapy?
Roman Ganzer (Germany)

(3,60MB)

Session 6

Focal therapy by Electroporation
Maurizio Brausi (Italy)

N/A

Results of the 3-year phase 2 program with TOOKAD^®Soluble
A. Rahmene Azzouzi (France)

(719KB)

TOOKAD^®Soluble: The  randomized parallel group European Phase 3 study comparing active treatment versus Active Surveillance
Mark Emberton (United Kingdom)

N/A

Has radiotherapy the potential to be focal?
George Kovacs (Germany)

(4,83MB)

SPONSORS